Results 1 to 10 of about 404,404 (258)

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer

EBioMedicine, 2022
Summary: Background: Previously, we uncovered a patient subgroup with highly malignant pancreatic cancer with serum markers CEA+/CA125+/CA19-9 ≥ 1000 U/mL (triple-positive, TP).
Longyun Ye, Kaizhou Jin, Zhenyu Liao, Zhiwen Xiao, Huaxiang Xu, Xuan Lin, Hao Li, Tianjiao Li, Wuhu Zhang, Xuan Han, Wenquan Wang, Heli Gao, Liang Liu, Weiding Wu, Xianjun Yu   +14 more
doaj   +1 more source

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Journal of Hematology & Oncology, 2022
Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong, Rong Tang, Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu, Si Shi   +8 more
doaj   +1 more source

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma

Oncogenesis, 2022
Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian, Yitao Gong, Xuan Zou, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Yesiboli Tasiheng, Xuan Lin, Xu Wang, Guopei Luo, Xianjun Yu, He Cheng, Chen Liu   +13 more
doaj   +1 more source

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma

World Journal of Surgical Oncology, 2021
Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong, Yunzhen Qian, Guopei Luo, Yu Liu, Ruijie Wang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Weiding Wu, Chen Liu   +11 more
doaj   +1 more source

Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas

World Journal of Surgical Oncology, 2022
Background Intraductal papillary mucinous neoplasms (IPMNs) are characterized by their abundant mucin production and malignant potential. IPMNs of the pancreas are mainly managed according to their radiographic indications, but this approach lacks ...
Yunzhen Qian, Yitao Gong, Guopei Luo, Yu Liu, Ruijie Wang, Xuan Zou, Shengming Deng, Xuan Lin, Yusheng Chen, Xu Wang, Xianjun Yu, He Cheng, Chen Liu   +12 more
doaj   +1 more source

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy

Cancer Control, 2020
Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer.
Chen Liu MD, PhD, He Cheng MD, Kaizhou Jin MD, PhD, Zhiyao Fan MD, Yitao Gong MD, Yunzhen Qian MD, Shengming Deng MD, Qiuyi Huang MD, Quanxing Ni MD, Xianjun Yu MD, PhD, Guopei Luo MD, PhD   +10 more
doaj   +1 more source

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)

Trials, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Radical surgical resection offers the only potential cure. There is increasing agreement that radical antegrade modular pancreatosplenectomy (RAMPS) may benefit ...
Jialin Li, Si Shi, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Hang Xu, Miaoyan Wei, Bo Zhang, Jin Xu, Wei Wang, Xianjun Yu   +11 more
doaj   +1 more source

ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells

Cancer Cell International, 2021
Background ALDOA is a glycolytic enzyme found mainly in developing embryos, adult muscle and various malignant tumours, including pancreatic tumours. Our previous study revealed that ALDOA, an oncogene, can promote the proliferation and metastasis of ...
Haidi Chen, Zeng Ye, Xiaowu Xu, Yi Qin, Changfeng Song, Guixiong Fan, Haifeng Hu, Yuheng Hu, Xianjun Yu, Wensheng Liu, Shunrong Ji, Wenyan Xu   +11 more
doaj   +1 more source

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis

Molecular Cancer, 2021
Background Extensive studies have demonstrated the pivotal roles of circular RNAs (circRNAs) in the occurrence and development of different human cancers. However, the expression and regulatory roles of circRNAs in pancreatic ductal adenocarcinoma (PDAC)
Zeyin Rong, Si Shi, Zhen Tan, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Wei Wang, Xianjun Yu, Chen Liang   +10 more
doaj   +1 more source

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Journal of Hematology & Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy.
Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu   +10 more
doaj   +1 more source